OTCMKTS:RHHBY

Roche Holding Ag Stock News

Healthcare > Drug Manufacturers - General

Buy RHHBY

*Your capital is at risk

$49.06

-0.130 (-0.264%)

At Close: Jun 03, 2026

Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference

02:00am, Monday, 17'th Mar 2025

Basel, 17 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, fro

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

12:08pm, Wednesday, 12'th Mar 2025

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

10:24am, Wednesday, 12'th Mar 2025

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.

Roche And Zealand Team Up To Develop Petrelintide

10:15am, Wednesday, 12'th Mar 2025

Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pi

RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug

09:30am, Wednesday, 12'th Mar 2025

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate.

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

06:55am, Wednesday, 12'th Mar 2025

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as

Roche takes big step in weight-loss field with $5.3 billion deal.

05:32am, Wednesday, 12'th Mar 2025

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.

Roche to develop, commercialize obesity drug with Zealand Pharma

02:17am, Wednesday, 12'th Mar 2025

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn

Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity

02:00am, Wednesday, 12'th Mar 2025

Basel, 12 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

02:00am, Wednesday, 12'th Mar 2025

Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people wit

Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard's Enterprise Research Campus in Allston

01:00am, Friday, 07'th Mar 2025

Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard's Enterprise Research Campus in Allston which will furt

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by